Halogen In Acid Moiety Patents (Class 560/47)
  • Patent number: 10189760
    Abstract: Disclosed is a method for synthesizing a sitagliptin intermediate, the method comprising: in the presence of hydrogen and a transition metal catalyst having a chiral phosphine ligand, subjecting a compound of formula II to an asymmetric reductive amination with ammonia or ammonium salt in a proper organic solvent under the condition of adding an acidic additive to produce a compound of formula I, wherein, an R- or S-configuration of a stereocenter is represented by *; the compound of formula I of R configuration can be used to prepare sitagliptin, and a reaction formula is as follows: R1 and R2 are each independently selected from hydrogen, C1-C12 linear or branched alkyl, C3-C12 cycloalkyl, C2-C12 alkenyl, C2-C12 alkynyl and C7-C12 arylalkyl. The method has a high yield and a high ee % value, a mild reaction condition and a low production cost, and is simple to operate, convenient to purify, environmental friendly and suitable for industrial production.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: January 29, 2019
    Assignees: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD., SHANGHAI SYNCORES TECHNOLOGIES INC. LTD.
    Inventors: Jian Hong, Yusheng Wang, Boyu Wang, Luning Huang, Eric Gu
  • Patent number: 9873651
    Abstract: Disclosed is a method for synthesizing a sitagliptin intermediate, the method comprising: in the presence of hydrogen and a transition metal catalyst having a chiral phosphine ligand, subjecting a compound of formula II to an asymmetric reductive amination with ammonia or ammonium salt in a proper organic solvent under the condition of adding an acidic additive to produce a compound of formula I, wherein, an R- or S-configuration of a stereocenter is represented by *; the compound of formula I of R configuration can be used to prepare sitagliptin, and a reaction formula is as follows: R1 and R2 are each independently selected from hydrogen, C1-C12 linear or branched alkyl, C3-C12 cycloalkyl, C2-C12 alkenyl, C2-C12 alkynyl and C7-C12 arylalkyl. The method has a high yield and a high ee % value, a mild reaction condition and a low production cost, and is simple to operate, convenient to purify, environmental friendly and suitable for industrial production.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: January 23, 2018
    Assignees: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD, SHANGHAI SYNCORES TECHNOLOGIES INC. LTD.
    Inventors: Jian Hong, Yusheng Wang, Boyu Wang, Luning Huang, Eric Gu
  • Patent number: 9238615
    Abstract: The present invention relates to a process for the preparation of iodinated anilines; in particular, it relates to a process including the direct iodination, with suitably activated iodine, of 3,5-disubstituted anilines to the corresponding 3,5-disubstituted-2,4,6-triiodoanilines, which are useful intermediates for the synthesis of x-ray contrast media, and to the preparation of the contrast media themselves.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: January 19, 2016
    Assignee: BRACCO IMAGING S.P.A.
    Inventors: Attilio Citterio, Luciano Lattuada, Gabriella Leonardi, Fulvio Uggeri, Evelin Vignale, Massimo Visigalli, Aurelia Ferrigato, Gabriele Meli, Roberta Fretta, Roberta Mazzon
  • Publication number: 20150148550
    Abstract: Disclosed is a novel compound to function as a calcium-dependent chloride channel blocking agent.
    Type: Application
    Filed: November 27, 2013
    Publication date: May 28, 2015
    Applicant: Korea Institute of Science and Technology
    Inventors: Eun Joo ROH, Changjoon Justin LEE, Soo Jin OH, Jong Hoon JUNG
  • Publication number: 20150051419
    Abstract: The present invention relates to processes for the preparation of quinoline-3-carboxamide derivatives, such as sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate (Laquinimod sodium). The present invention further relates to intermediates formed in such processes.
    Type: Application
    Filed: August 28, 2014
    Publication date: February 19, 2015
    Applicant: MAPI PHARMA LTD.
    Inventors: Ehud MAROM, Michael MIZHIRITSKII, Shai RUBNOV
  • Patent number: 8927604
    Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: January 6, 2015
    Assignee: APR Applied Pharma Research s.a.
    Inventors: Giorgio Reiner, Alberto Reiner
  • Patent number: 8785494
    Abstract: The invention relates to novel calcium-sensing receptor (CaSR) modulating trifluoromethylphenylene cyclopentylene compounds represented in formula (I) and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: July 22, 2014
    Assignee: LEO-Pharma A/S
    Inventor: Bjarne Nørremark
  • Patent number: 8686185
    Abstract: The present invention provides an efficient method for mass-producing 2-hydroxy-5-(substituted)phenylalkylamino benzoic acid derivatives represented by specific Chemical formulas or their salts, particularly 2-hydroxy-5-[2-(4-trifluoromethylphenyl)ethylamino]benzoic acid or its salt.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: April 1, 2014
    Assignee: Neurotech Pharmaceuticals Co., Ltd.
    Inventors: Byoung Joo Gwag, Jae Young Cho, Young Ae Lee, Cheng Qiling, Yulian Wu, Li Xing
  • Publication number: 20140039009
    Abstract: The invention relates to compounds of structural formulas (I), (VII) and (XI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, Y, Z, L, R1, R2, R3, R18 and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 6, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Lijun Sun, Shoujun Chen, Zhiqiang Xia, Jun Jiang, Yu Xie, Junyi Zhang
  • Publication number: 20140031370
    Abstract: A compound represented by Formula (1): The compound can be used as insecticides.
    Type: Application
    Filed: September 20, 2013
    Publication date: January 30, 2014
    Applicant: MITSUI CHEMICALS, INC.
    Inventors: Kei Yoshida, Takeo Wakita, Hiroyuki Katsuta, Akiyoshi Kai, Yutaka Chiba, Kiyoshi Takahashi, Hiroko Kato, Nobuyuki Kawahara, Michikazu Nomura, Hidenori Daido, Junji Maki, Shinichi Banba
  • Publication number: 20140018422
    Abstract: Disclosed herein are derivatives of tetracaine that, among other things, block cyclic nucleotide gated (CNG) channels and are useful in the treatment of diseases characterized by overactive CNG channels such as retinal degeneration diseases.
    Type: Application
    Filed: December 14, 2012
    Publication date: January 16, 2014
    Inventors: Jeffrey Karpen, Sarah Kirk, Adriana Andrade, Michelle Schaffer, Kenneth Melich
  • Publication number: 20130296332
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Application
    Filed: July 1, 2013
    Publication date: November 7, 2013
    Inventors: Hans ALLGEIER, Yves AUBERSON, David CARCACHE, Philipp FLOERSHEIM, Christel GUIBOURDENCHE, Wolfgang FROESTL, Jörg KALLEN, Manuel KOLLER, Henri MATTES, Joachim NOZULAK, David ORAIN, Johanne RENAUD
  • Publication number: 20130245065
    Abstract: The present invention relates to processes for the preparation of quinoline-3-carboxamide derivatives, such as sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate (Laquinimod sodium). The present invention further relates to intermediates formed in such processes.
    Type: Application
    Filed: November 28, 2011
    Publication date: September 19, 2013
    Applicant: MAPI PHARMA LTD.
    Inventors: Ehud Marom, Michael Mizhiritskii, Shai Rubnov
  • Patent number: 8466081
    Abstract: Disclosed are halogenated amide esters that are suitable as internal electron donors in procatalyst compositions. Ziegler-Natta catalyst compositions containing the present procatalyst compositions exhibit improved catalyst activity and/or improved catalyst selectivity and produce propylene-based olefins with broad molecular weight distribution.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: June 18, 2013
    Assignee: Dow Global Technologies LLC
    Inventors: Linfeng Chen, Tak W. Leung, Tao Tao, Kuanqiang Gao, James X. Shu
  • Publication number: 20130109856
    Abstract: The present invention relates to a novel process for the preparation of compounds of general formula (I) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.
    Type: Application
    Filed: October 29, 2012
    Publication date: May 2, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventor: Boehringer Ingelheim International GmbH
  • Publication number: 20130096151
    Abstract: The present invention relates to the use of an anesthetic agent for killing clinically latent microorganisms associated with microbial infections and to novel combinations comprising an anesthetic agent and an antimicrobial agent for the treatment of microbial infections.
    Type: Application
    Filed: March 29, 2011
    Publication date: April 18, 2013
    Applicant: HELPERBY THERAPEUTICS LIMITED
    Inventors: Yanmin Hu, Anthony M.R. Coates
  • Patent number: 8304513
    Abstract: Disclosed are polyesters, particularly poly(trimethylene terephthalate), comprising fluorovinylether functionalized aromatic repeat units, and methods to make the polyester polymers. The polymers are useful for imparting soil resistance to polyesters, particularly in the form of fibers, fabrics, and carpets.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: November 6, 2012
    Assignee: E I du Pont de Nemours and Company
    Inventors: Neville Everton Drysdale, Surbhi Mahajan, Kenneth Gene Moloy, Fredrik Nederberg, Joel M. Pollino, Joachim C. Ritter
  • Publication number: 20120129926
    Abstract: The invention relates to novel calcium-sensing receptor (CaSR) modulating trifluoromethylphenylene cyclopentylene compounds represented in formula (I) and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.
    Type: Application
    Filed: May 26, 2010
    Publication date: May 24, 2012
    Applicant: LEO PHARMA A/S
    Inventor: Bjarne Nørremark
  • Publication number: 20120088926
    Abstract: The present invention describes a process for the synthesis of a iodinating agent, being said iodinating agent iodine chloride (ICI.) In particular, the present invention relates to a process for the electrochemical preparation of ICI, as a useful iodinating agent in the preparation of iodinated organic compounds for use as contrast agents or their precursors in the synthesis of the same.
    Type: Application
    Filed: July 6, 2010
    Publication date: April 12, 2012
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Pier Lucio Anelli, Carlo Felice Viscardi, Pietro Delogu, Fabrizio Goffredi, Alfonso Nardelli, Giovanni Battista Giovenzana
  • Publication number: 20120041224
    Abstract: The present invention relates to a process for the preparation of iodinated anilines; in particular, it relates to a process including the direct iodination, with suitably activated iodine, of 3,5-disubstituted anilines to the corresponding 3,5-disubstituted-2,4,6-triiodoanilines, which are useful intermediates for the synthesis of x-ray contrast media, and to the preparation of the contrast media themselves.
    Type: Application
    Filed: April 8, 2010
    Publication date: February 16, 2012
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Attilio Citterio, Luciano Lattuada, Gabriella Leonardi, Fulvio Uggeri, Evelin Vignale, Massimo Visigalli, Aurelia Ferrigato, Gabriele Meli, Roberta Fretta, Roberta Mazzon
  • Patent number: 8097267
    Abstract: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: January 17, 2012
    Assignee: APR Applied Pharma Research s.a.
    Inventors: Giorgio Reiner, Alberto Reiner
  • Patent number: 8097651
    Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
    Type: Grant
    Filed: January 7, 2010
    Date of Patent: January 17, 2012
    Assignee: APR Applied Pharma Research s.a.
    Inventors: Giorgio Reiner, Alberto Reiner, Andreas Meyer
  • Publication number: 20110082111
    Abstract: Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: December 7, 2010
    Publication date: April 7, 2011
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Sheldon X. Cao, Victoria Feher, Takashi Ichikawa, Benjamin Jones, Stephen W. KALDOR, Andre A. KIRYANOV, Betty Lam, Yan Liu, Christopher McBride, Srinivasa Reddy Natala, Zhe Nie, Jeffrey A. Stafford
  • Patent number: 7759394
    Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: July 20, 2010
    Assignee: APR Applied Pharma Research SA
    Inventors: Giorgio Reiner, Alberto Reiner, Andreas Meyer
  • Publication number: 20100145065
    Abstract: Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-1 and their synthetic intermediates: wherein Z, X1, X2, X5, R2 and R10 are as defined herein. Compounds of Formula Ia-1 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.
    Type: Application
    Filed: June 21, 2006
    Publication date: June 10, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: John Demattei, Sagar Shakya, Anthony D. Piscopio, Bruno P. Hache, Matthew Charles Evans, James Gair Ford, Simon Mark Pointon, Koen Peeters, Timothy John Lilley, John Leonard
  • Patent number: 7700125
    Abstract: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms.
    Type: Grant
    Filed: February 7, 2006
    Date of Patent: April 20, 2010
    Assignee: Kowa Pharmaceuticals America, Inc.
    Inventors: Giorgio Reiner, Alberto Reiner
  • Patent number: 7625948
    Abstract: A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1?) (wherein R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R10)—; R3 and R4 are each hydrogen atom, C1-C6alkyl or C1-C6alkoxy, etc.; R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R8 and R9 are each independently hydrogen atom, C1-C6alkyl, —CON(R18)(R19) or —COO(R20), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk1 and Alk2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: December 1, 2009
    Assignee: Japan Tobacco Inc.
    Inventors: Atsushi Hagiwara, Yasuhiro Ohe, Naoya Odani, Shizue Watanabe, Taku Ikenogami, Takashi Kawai, Kenya Madono, Toshio Taniguchi
  • Publication number: 20090163457
    Abstract: The invention relates to codrugs having improved properties, methods for preparing and administering them, and methods of formulating and administering the codrugs as pharmaceutical preparations. In certain embodiments, the codrugs can be locally administered to deliver the constituent biologically active compound in a sustained-release fashion, reducing systemic concentrations of the biologically active compound.
    Type: Application
    Filed: November 26, 2008
    Publication date: June 25, 2009
    Applicant: pSivida, Inc.
    Inventors: Paul Ashton, Jianbing Chen, Hong Guo, Grazyna Cynkowska, Tadeusz Cynkowski
  • Patent number: 7538140
    Abstract: A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1?) (wherein R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R10)—; R3 and R4 are each hydrogen atom, C1-C6alkyl or C1-C6alkoxy, etc.; R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R8 and R9 are each independently hydrogen atom, C1-C6alkyl, —CON(R18)(R19) or —COO(R20), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk1 and Alk2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: May 26, 2009
    Assignee: Japan Tobacco Inc
    Inventors: Atsushi Hagiwara, Yasuhiro Ohe, Naoya Odani, Shizue Watanabe, Taku Ikenogami, Takashi Kawai, Kenya Madono, Toshio Taniguchi
  • Publication number: 20090029947
    Abstract: The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.
    Type: Application
    Filed: March 11, 2008
    Publication date: January 29, 2009
    Inventors: Grier A. Wallace, Eric C. Breinlinger, Kevin P. Cusack, Shannon R. Fix-Stenzel, Thomas D. Gordon, Adrian D. Hobson, Martin E. Hayes, Graham K. Ansell, Pintipa Grongsaard
  • Patent number: 7408078
    Abstract: The present invention provides pharmaceutical compositions useful in treating hepatitis C infection. The present invention also provides methods of treating hepatitis C infection by administering to a mammal the pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: October 8, 2003
    Date of Patent: August 5, 2008
    Assignees: Wyeth, ViroPharma Incorporated
    Inventors: Jonathan D. Bloom, Thomas R. Bailey
  • Patent number: 7408076
    Abstract: Disclosed are 2-bromoaniline or 2-chloroaniline compounds of formula (I): wherein R, R1 and X are as defined. The compounds are useful as intermediates for preparing indole compounds.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: August 5, 2008
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Guisheng Li, Jianxiu Liu, Zhi-Hui Lu, Frank Roschangar, Chris Hugh Senanayake, Ming Shen
  • Patent number: 7371867
    Abstract: One aspect of the invention relates to hexafluoroleucine and congeners thereof, and methods of making the compounds. Another aspect of the invention relates to the synthesis of protein cores comprising hexafluoroleucine and congeners thereof. Certain peptides comprising hexafluoroleucine and congeners thereof have been characterized using comparative biophysical studies. In general, the fluorinated peptides show higher thermal stability and enhanced resistance to chemical denaturation. Further, mixed hydrocarbon-fluorocarbon cores self-sort into homogeneous bundles, suggesting new avenues for the design and manipulation of protein-protein interfaces.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: May 13, 2008
    Assignee: Trustees of Tufts College
    Inventors: Alfio Fichera, Zihni Bilgicer, Krishna Kumar, Xuechao Xing
  • Patent number: 7371896
    Abstract: The present invention relates to a tetrafluorobenzyl derivative and a pharmaceutical composition for prevention and treatment of acute and chronic neurodegenerative disease in central nervous system and ophthalmic diseases containing the same. The tetrafluorobenzyl derivative of the present invention can effectively be used to prevent and treat chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, degenerative brain disease such as epilepsy and ischemic brain disease such as stroke.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: May 13, 2008
    Assignee: AmKor Pharma, Inc.
    Inventors: Byoung-Joo Gwag, Sung-Hwa Yoon, Ho-Sang Moon, Eun-Chan Park, Seok-Joon Won, Young-Ae Lee, Hae-Un Lee
  • Patent number: 7319160
    Abstract: The present invention relates to a tetrafluorobenzyl derivative and a pharmaceutical composition for prevention and treatment of acute and chronic neurodegenerative disease in central nervous system and ophthalmic diseases containing the same. The tetrafluorobenzyl derivative of the present invention can effectively be used to prevent and treat chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, degenerative brain disease such as epilepsy and ischemic brain disease such as stroke.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: January 15, 2008
    Assignee: AmKor Pharma, Inc.
    Inventors: Byoung Joo Gwag, Sung Hwa Yoon, Ho Sang Moon, Eun Chan Park, Seok Joon Won, Young Ae Lee, Hae Un Lee
  • Patent number: 7262209
    Abstract: The invention relates to compounds of the general formula wherein Ar1, Ar2, R4, R5, R6, R7, R8, W, X, a and b have the significances given in the specification, and optionally the enantiomers thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling parasites on warm-blooded animals.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: August 28, 2007
    Assignee: Novartis Animal Health US, Inc.
    Inventors: Thomas Goebel, Pierre Ducray
  • Patent number: 7132559
    Abstract: One aspect of the invention relates to hexafluoroleucine and congeners thereof, and methods of making the compounds. Another aspect of the nvention relates to the synthesis of protein cores comprising hexafluoroleucine and congeners thereof. Certain peptides comprising hexafluorleucine and congeners thereof have been characterized using comparative biophysical studies. In general, the fluorinated peptides show higher thermal stability and enhanced resistance to chemical denaturation. Further, mixed hydrocarbonfluorocarbon cores self-sort into homogeneous bundles, suggesting new avenues for the design and manipulation of protein-protein interfaces.
    Type: Grant
    Filed: February 25, 2002
    Date of Patent: November 7, 2006
    Assignee: Trustees of Tufts College
    Inventors: Alfio Fichera, Zihni Bilgicer, Krishna Kumar, Xuechao Xing
  • Patent number: 7115662
    Abstract: Disclosed are the compounds of formula I wherein R is methyl or ethyl; R1 is chloro or fluoro; R2 is hydrogen or fluoro; R3 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R4 is hydrogen or fluoro; and R5 is chloro, fluoro, trifluoromethyl or methyl; and pharmaceutically acceptable salts thereof, as selective COX-2 cyclooxygenase inhibitors; and pharmaceutically acceptable prodrug esters thereof.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: October 3, 2006
    Assignee: Novartis AG
    Inventors: Roger A Fujimoto, Leslie W McQuire, Benjamin B Mugrage, John H Van Duzer, Daqiang Xu
  • Patent number: 7084281
    Abstract: A novel synthesis reaction for highly stereospecific tri- and tetra-substituted olefins is described. A single stereoisomer of stable ?-halo-?,?-ester is produced in high yield by the reaction of aldehyde or ketone with a trihalogenated compound such as trichloroacetate in the presence of CrCl2 in a solvent. By varying the amount of CrCl2 used, the stable dihalohydrin intermediate may be obtained as well.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: August 1, 2006
    Assignee: Board of Regents, The University of Texas System
    Inventors: John R. Falck, Deb K. Barma, Abhijit Kundu
  • Patent number: 7034015
    Abstract: The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compounds, and to the use of said compounds in the manufacture of pharmaceutical preparations.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: April 25, 2006
    Assignee: Leo Pharma A/S
    Inventors: Erik Rytter Ottosen, Anne Marie Horneman, Xifu Liang
  • Patent number: 6974595
    Abstract: New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: December 13, 2005
    Assignee: ProEthic Pharmaceuticals, Inc.
    Inventors: Alberto Reiner, Giorgio Reiner
  • Patent number: 6930200
    Abstract: Mono-substituted and di-substituted alpha-amino acids and derivatives thereof, substituted at the alpha positon with one (mono-) or two (di-) substituents (R2 and/or R3) as shown in Formula 1: N(R4R5)C(R2R3)CO(OR1).
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: August 16, 2005
    Assignee: Pharmacore, Inc.
    Inventor: Adnan M. M. Mjalli
  • Patent number: 6924082
    Abstract: The present application describes a method for information storage and data processing comprising the steps of thermo inducing or photo inducing double-bond shifts (DBS) in substituted (4n)-annulenes thus generating transitions between two different conjugation states with at least one substituent. The two different conjugation states are the conjugation on-state and conjugation off-state of the annulene core ?-electrons with the substituent ?-electrons. The present invention is furthermore related to novel substituted (4n)-heptalenes being optically and/or thermally switchable, based on thermal or photochemical double-bond shifts (DBS) as well as methods for their preparation. The (4n)-heptalenes can be used for information storage and data processing devices.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: August 2, 2005
    Assignee: Ciba Specialty Chemicals Corporation
    Inventor: Hans-Jürgen Hansen
  • Patent number: 6852876
    Abstract: The novel compound of the disclosure is 4-chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19), and it alone or in combination with 4-(4-Ethoxy-phenyl)-2-(N?-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OF-13), appears useful in humans as therapeutic means for the eradication of tumors from the human's colon.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: February 8, 2005
    Assignee: University of Central Florida
    Inventors: D. Howard Miles, Solodnikov Sergey Yurjevich, Lisovskaja Natalja Anatoljevna, Elena A. Goun
  • Patent number: 6835848
    Abstract: The present invention relates to a new and industrially advantageous one-pot process for the preparation of alkyl 3-cyclopropyl amino-2-[2,4-dibromo-3-(difluoromethoxy) benzoyl]-2-propenoates of in which R represents methyl or ethyl, which are valuable intermediates for the production of highly active antibacterial quinolone medicaments.
    Type: Grant
    Filed: January 6, 2003
    Date of Patent: December 28, 2004
    Assignees: Ranbaxy Laboratories Limited, Toyama Chemical Co., Ltd.
    Inventors: Prosenjit Bose, Naresh Kumar, Taro Kiyoto
  • Patent number: 6831102
    Abstract: New thyroid receptor ligands are provided which have the general formula I: wherein R1 is halogen, trifluoromethyl, substituted or unsubstituted aryl, substituted or unsubstituted C1-6 alkyl, or substituted or unsubstituted C3-7 cycloalkyl; R2 and R3 are each independently hydrogen, halogen, substituted or unsubstituted C1-4 alkyl, or substituted or unsubstituted C3-6 cycloalkyl, wherein at least one of R2 and R3 is other than hydrogen; R4 is a carboxylic acid selected from the group consisting of (CH2)nCOOH, (CH)2COOH, NHCO(CH2)nCOOH, CONH(CH2)nCOOH and NH(CH2)mCOOH; n is an integer from 0 to 4; and m is an integer from 1 to 4. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: December 14, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventor: Jon J. Hangeland
  • Patent number: 6727281
    Abstract: Disclosed are the compounds of formula I wherein R is methyl or ethyl; R1 is chloro or fluoro; R2 is hydrogen or fluoro; R3 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R4 is hydrogen or fluoro; and R5 is chloro, fluoro, trifluoromethyl or methyl; and pharmaceutically acceptable salts thereof, as selective COX-2 cyclooxygenase inhibitors; and pharmaceutically acceptable prodrug esters thereof.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: April 27, 2004
    Assignee: Novartis AG
    Inventors: Roger A. Fujimoto, Leslie W. McQuire, Benjamin B. Mugrage, John H. van Duzer
  • Patent number: 6723345
    Abstract: Topical gelled compositions comprising an optional drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: April 20, 2004
    Assignee: L.A.M. Pharmaceutical Corp.
    Inventors: Alan Drizen, Peter Rothbart, Gary M. Nath
  • Patent number: 6667413
    Abstract: The present invention relates to an uracil compound of the formula [I]: wherein W represents oxygen, sulfur, imino or C1 to C3 alkylimino; Y represents oxygen, sulfur, imino or C1 to C3 alkylimino; R1 represents C1 to C3 alkyl or C1 to C3 haloalkyl; R2 represents C1 to C3 alkyl; R4 represents hydrogen or methyl; R5 represents C1 to C6 alkyl, C1 to C6 haloalkyl, or the like; X1 represents halogen, cyano or nitro; X2 represents hydrogen or halogen; and each of X3 and X4 independently represents hydrogen, halogen, C1 to C6 alkyl, or the like. The present compound has an excellent herbicidal activity.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: December 23, 2003
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Yoshitomo Tohyama, Yuzuru Sanemitsu, Tomohiko Gotou
  • Patent number: 6620962
    Abstract: According to the invention, N-butyryl-4-amino-3-methyl-methyl benzoate is obtained in a particularly advantageous manner by, initially, reacting o-toluidine with butyric acid chloride, by brominating the reaction product and by reacting the bromide obtained therefrom with carbon monoxide and methanol in the presence of a palladium catalyst. The invention also relates to the important novel chemical compound N-(4-bromine-2-methylphenyl)-butanamide.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: September 16, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Lars Rodefeld, Thomas Höpfner, Alexander Klausener, Horst Behre